|
|
|
ECOG-E1609
|
A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon Alpha-2b for Resected High-Risk Melanoma |
III |
Immunotherapy |
interferon alfa-2b; ipilimumab |
|
09-131
|
Phase II Study of Proton Beam Irradiation for the Treatment of Unresectable Hepatocellular Cancer and Cholangiocarcinoma |
II |
Proton Therapy |
Not Applicable |
|
UPCC-01712
|
Single Arm Salvage Therapy With Pegylated Interferon Alfa-2a for Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who Are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis |
II |
Anti-inflammatory Agent |
pegylated interferon |
|
UPCC 23811
|
A Phase 2 Study of Dovitinib in Adults With Advanced Malignant Pheochromocytoma or Paraganglioma |
II |
Signal Transduction Inhibitor |
dovitinib |
|
INCB 39110-230
|
An Open-Label, Multiple Simon 2-Stage Study of INCB039110 Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF) |
II |
Other |
INCB039110 |
|
UPCC-29212
|
A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) |
I |
Signal Transduction Inhibitor |
GSK525762 |
|
UPCC - 13212
|
A Phase 1 Study of LY2801653 in Patients With Advanced Cancer |
I |
c-MET Inhibitor |
LY2801653 |
|
CA186-011
|
A Phase 1 Study of the Safety, Tolerability, Pharmacokinetics and Immunoregulatory Activity of BMS-663513 (Anti-CD137) in Subjects With Advanced and/or Metastatic Solid Tumors |
I |
Immunotherapy |
BMS-663513 |
|
UPCC 09211
|
A Feasibility and Registration Study of Proton Radiotherapy for Upper Gastrointestinal Malignancies |
Not Specified |
Radiotherapy, Proton Therapy |
Not Applicable |